Skip to main content
. Author manuscript; available in PMC: 2021 Jul 15.
Published in final edited form as: Cancer Res. 2020 Nov 10;81(2):384–399. doi: 10.1158/0008-5472.CAN-20-1488

Figure 3. Functional role of FZD7 in OC cells.

Figure 3.

(A) FZD7 mRNA levels (mean fold-change ± SD, n=3–4) in FZD7 (+) and FZD7 (−) cells FACS selected from SKOV3, OVCAR5, and COV362 cells and HGSOC tumors. (B-D) Cell viability (mean fold-change ± SD, n=4) of FZD7(+) and FZD7(−) cells from OVCAR5 (n=3) (B), SKOV3 (n=3) (C) or COV362 (n=4) (D) cells, plated, treated with the indicated doses of CDDP for 24 hours, and cultured for additional three days. (E, F) Representative pictures and numbers (mean ± SD, n = 4–5) of spheroids formed after 7 days of culture by FZD7(+) and FZD7(−) cells FACS sorted from SKOV3 (E) and OVCAR5 (F) OC cells. Spheroids were counted or cell numbers were estimated by CellTiter-Glo 3D cell viability assay. (G-I) mRNA levels (fold-change ± SD) of Nanog in FZD7(+) compared with FZD7(−) cells from SKOV3 (G) (n=3), OVCAR5 (H) (n=8) and COV362 (I)(n=3) cells. For all comparisons: *P<0.05, **P<0.01, ***P<0.001.